In vitro chemosensitivity assay of ascites in epithelial ovarian cancer

European Journal of Gynaecological Oncology

Volumn 34, Issue 6, 2013, Pages 559-564

  Xu, X ^a,b,d   Dai, H ^c   Zhao, Y ^a,b   Wang, Y ^d   Qian, Z ^a,b   Chen, X ^a,b  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c YANGZHOU UNIVERSITY   (China)

^d Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine   (China)

Author keywords

Chemotherapy; Drug sensitivity assay; Epithelial ovarian cancer; MTT, ascites

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; PACLITAXEL; PLATINUM; PROTEIN P53; TOPOTECAN; ANTINEOPLASTIC AGENT; COLORING AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIRUBICIN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER PATIENT; CHEMOSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MTT ASSAY; OVARY CARCINOMA; PERSONAL EXPERIENCE; PREDICTIVE VALUE; PROTEIN EXPRESSION; RELAPSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR CELL; DISEASE COURSE; DRUG SCREENING; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE; TIME; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; ASCITES; CARBOPLATIN; COLORING AGENTS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; EPIRUBICIN; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898812278     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Siegel R., Naishadham D., Jemal A.: "Cancer statistics, 2012". CA. Cancer J. Clin., 2012, 62, 10.
2. Kapnick J., Helgason H.: "Indefinitely prolonged survival after relapse in advanced ovarian cancer the other end of the telescope". Gynecol. Oncol, 2009, 115, 317-8; author reply 9.
3. Markman M., Markman J., Webster K., Zanotti K., Kulp B., Peterson G. et al: "Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design". J. Clin. Oncol, 2004, 22, 3120.
4. Marchetti C, Pisano G, Facchini G., Bruni G. S., Magazzino F. P., Losito S. et al: "Tint-line treatment of advanced ovarian cancer. current research and perspectives". Expert. Rev. Anticancer. Ther., 2010, 10, 47.
5. Markman M: "Pharmaceutical management of ovarian cancer: current status". Drugs., 2008, 68, 771.
6. Ozols R. F.: "Advanced ovarian cancer a clinical update on firstline treatment, recurrent disease, and new agents". J. Natl Compr. Cane. Netw., 2004, 2(Suppl. 2), S60.
7. Nagai N., Minamikawa K., Mukai K., Hirata E., Komatsu M., Kobayasbi H.: "Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test". Anticancer Drugs., 2005, 16, 525.
8. Hirschhaeuser R, Menne H., Dittfeld C, West J., Mueller-Klieser W., Kunz-Schughart LA.: "Multicellular tumor spheroids: an underestimated tool is catching up again". J. Biotechn., 2010, 148, 3.
9. Payne G., Chun P., Tavares D. J.: "A CA6 antigen-specific cytotoxic conjugate and methods of using the same". E. P. Patent 1, 660, 513, 2012.
10. Wang Y. H., Xiong J., Wang S. F., Yu Y., Wang B., Chen Y. X. et al: "Lenti virus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo". Mol Cell. Biochem., 2010, 341, 225.
11. Hatok J., Babusikova E., Matakova T., Mistuna D., Dobrota D., Racay P.: "In vitro assays for the evaluation of drug resistance in tumor cells". Clin. Exp. Med., 2009, 9, 1.
12. Sato S., Itamochi H., Kigawa J., Oishi T., Shimada M., Naniwa J. et al: "Combination chemotherapy of oxaliplatin and 5-fiuorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy". Cancer science, 2009, 100, 546.
13. Sargent J. M.: "The use of the MTT assay to study drug resistance in fresh tumour samples". Recent Results Cancer Res., 2003, 161, 13.
14. Taylor C. G., Sargent J. M., Elgie A. W., Williamson C. J., Lewandowicz G. M., Chappatte O. et al.: "Chemosensitivity testing predicts survival in ovarian cancer". Eur. J. Gynaecol. Oncol., 2001, 22, 278.
15. Moertel C. G., Hanley J. A.: "The effect of measuring error on the results of therapeutic trials in advanced cancer". Cancer, 1976, 38, 388.
16. Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L. et al.: "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada". J. Natl. Cancer Inst., 2000, 92, 205.
17. Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R. et al.: "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) ". Eur. J. Cancer, 2009, 45, 228.
18. Hasovits C, Clarke S.: "Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics". Clin. PharmacoHnet., 2012, 51, 203.
19. De Bree E., Theodoropoulos P. A., Rosing H., Michalakis J., Romanos J., Beijnen J. H. et al.: "Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside". Cancer Treat. Rev., 2006, 32, 471.
20. Cree I. A., Kurbacher CM., Lamont A., Hindley A. C., Love S.: "A prospective randomized controlled trial of rumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer". Anticancer Drugs., 2007, 18, 1093.
21. Taylor C. G., Sargent J. M., Elgie A. W., Reid F. D., Alton P. A., Hill J. G.: "The clinical relevance of chemosensitivity testing in ovarian cancer". Cancer Detect. Prev., 1998, 22, 305.
22. Ferriss J. S., Rice L. W.: "The role of in vitro directed chemotherapy in epithelial ovarian cancer". Rev. Obstet. Gynecol., 2010, 3, 49.
23. Orr J. W. Jr., Orr P., Kern D. H.: "Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance". Cancer J. Sci. Am., 1999, 5, 174.
24. Ozols R. F., Bundy B. N., Greer B. E., Fowler J. M., Clarke-Pearson D., Burger R. A. et al.: "Phase HI trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study". J. Clin. Oncol., 2003, 21, 3194.
25. Markman M., Bundy B. N., Alberts D. S., Fowler J. M., Clark-Pearson D. L., Carson L. F. et al.: "Phase HJ trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume Stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group". J. Clin. Oncol., 2001, 19, 1001.
26. Shih Ie M., Kurman R. J.: "Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis". Am. J. Pathol, 2004, 164, 1511.
27. Kurman R. J., Shih Ie M.: "Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm". Hum. Pathol., 2011, 42, 918.
28. Krasner C. N., Poveda A., Herzog T. J., Vermorken IB., Kaye S. B., Nieto A. et al.: "Patient-reported outcomes in relapsed ovarian cancer results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone". Gynecol. Oncol, 2012, 127, 161.
29. Furukawa T, Kubota T., Watanabe M., Takahara T., Yamaguchi H., Takeuchi T. et al: "High in vitro in vivo correlation of drug response using sponge gel supported three dimensional histoculture and the MTT end point". Int. J. Cancer, 2006, 51, 489.
30. Suto A., Kubota T., Shimoyama Y., Ishibiki K., Abe O.: "MTT assay with reference to the clinical effect of chemotherapy". J. Surg. Oncol, 2006, 42, 28.